CLOS
CPRX

Compagnie Lombard Odier SCmA’s Catalyst Pharmaceutical CPRX Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,000
Closed -$33K – 655
2020
Q4 		$33K Hold
10,000
– – ﹤0.01% 478
2020
Q3 		$30K Hold
10,000
– – ﹤0.01% 432
2020
Q2 		$46K Hold
10,000
– – ﹤0.01% 382
2020
Q1 		$38K Buy
+10,000
New +$41K ﹤0.01% 364

Other funds holding CPRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Compagnie Lombard Odier SCmA's CPRX Position: Q1 2021 in Review

Compagnie Lombard Odier SCmA sold out of Catalyst Pharmaceutical (CPRX) in Q1 2021, closing a stake of 10,000 shares — an estimated $33K sold.

Compagnie Lombard Odier SCmA first reported a position in CPRX in Q1 2020 and held it in 4 quarters. The position peaked at $46K in Q2 2020. 133 funds tracked by Wall St. Rank hold CPRX as of Q1 2021.

  • Compagnie Lombard Odier SCmA reported no remaining Catalyst Pharmaceutical position as of Q1 2021 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 10,000 Catalyst Pharmaceutical shares in Q1 2021, an estimated $33K.
  • Compagnie Lombard Odier SCmA first reported a position in Catalyst Pharmaceutical in Q1 2020 and held it in 4 quarters.
  • Compagnie Lombard Odier SCmA's Catalyst Pharmaceutical position peaked at $46K in Q2 2020.
  • 133 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2021.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q1 2021, filed 23 Apr 2021.